stearates and Carcinoma--Lewis-Lung

It is necessary to discover a novel antitumor liposome with prolonged circulation time, high efficacy, and low cost. Here, we reported a liposomal honokiol (HNK) prepared with a new type of excipient, Kolliphor HS15, which was termed as HS15-LP-HNK. In addition, we employed PEGylated liposomal honokiol (PEG-LP-HNK) as positive control. The HS15-LP-HNK was prepared by thin-film hydration method. It was near-spherical morphology with an average size of 80.62 ± 0.72 nm (PDI = 0.234 ± 0.007) and a mean zeta potential of -3.91 ± 0.06 mv. In vivo studies exhibited no significant difference between HS15-LP-HNK and PEG-LP-HNK. The pharmacokinetic and biodistribution results showed that HS15-LP-HNK could improve the bioavailability and increase tumor accumulation of honokiol. Furthermore, HS15-LP-HNK could enhance antitumor efficacy of honokiol with low toxicity. In summary, HS15-LP-HNK is promising in tumor targeted drug delivery system.

Topics: Animals; Antineoplastic Agents, Phytogenic; Biological Availability; Biphenyl Compounds; Carcinoma, Lewis Lung; Cell Line, Tumor; Drug Carriers; Drug Compounding; Drug Screening Assays, Antitumor; Excipients; Female; Humans; Lignans; Liposomes; Magnolia; Mice; Mice, Inbred C57BL; Polyethylene Glycols; Rats; Rats, Wistar; Stearates; Tissue Distribution